

IN THE CLAIMS:

Claim 1, line 14 (counting the structural formulae as one line and disregarding the numbering in the left-hand margin), please delete "optionally" and insert --unsubstituted or--.

Claim 8, line 3, please delete "and" (first occurrence) and insert --or a--;  
line 3, please delete "salts and solvates" and insert --salt or solvate--.

Claim 9, line 16, please delete "and" (first occurrence) and insert --or a--;  
line 16, please delete "salts and solvates" and insert --salt or solvate--.

Claim 11, line 1, please delete "7" and insert --8--.

Claim 12, line 1, please delete "7" and insert --8--.

Please cancel claims ~~13-21~~ without prejudice or disclaimer and add the following claims to the application:

<sup>13</sup>  
B<sup>1</sup> ~~22~~. A pharmaceutical composition which comprises an effective amount of a compound of formula (I) as defined in claim 1 or a physiologically acceptable salt or solvate thereof together with at least one physiologically acceptable carrier or excipient.--

<sup>14</sup>  
~~23~~. A pharmaceutical composition according to claim <sup>13</sup>~~22~~ in a form adapted for oral or parenteral administration.--

<sup>15</sup>  
~~24~~. A pharmaceutical composition according to claim <sup>13</sup>~~22~~ wherein the active ingredient is 2,3,4,5-tetrahydro-5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-1H-pyrido[4,3-b]indol-1-one or a physiologically acceptable salt or solvate thereof.--

<sup>16</sup>  
~~25~~. A pharmaceutical composition according to claim <sup>13</sup>~~22~~ wherein the active ingredient is 2,3,4,5-tetrahydro-5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-1H-pyrido[4,3-b]indol-1-one hydrochloride.--



D 17  
--26. A method of treating a condition which <sup>is</sup> ~~may be~~ ameliorated by antagonism of 5HT<sub>3</sub> receptors which comprises administering to a patient an effective amount of a compound of formula (I) as defined in claim 1 or a physiologically acceptable salt or solvate thereof to relieve said condition.--

18 17  
--27. A method according to claim <sup>17</sup>26 wherein the compound of formula (I) is 2,3,4,5-tetrahydro-5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-1H-pyrido[4,3-b]indol-1-one or a physiologically acceptable salt or solvate thereof.--

19 17  
--28. A method according to claim <sup>17</sup>26 wherein the compound of formula (I) is 2,3,4,5-tetrahydro-5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-1H-pyrido[4,3-b]indol-1-one hydrochloride.--

D 20 17  
--29. A method according to claim <sup>17</sup>26 wherein the condition which <sup>is</sup> ~~may be~~ ameliorated by antagonism of 5HT<sub>3</sub> receptors is anxiety.--

21 20  
--30. A method according to claim <sup>20</sup>29 wherein the compound of formula (I) is 2,3,4,5-tetrahydro-5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-1H-pyrido[4,3-b]indol-1-one or a physiologically acceptable salt or solvate thereof.--

22 20  
--31. A method according to claim <sup>20</sup>29 wherein the compound of formula (I) is 2,3,4,5-tetrahydro-5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-1H-pyrido[4,3-b]indol-1-one hydrochloride.--

D 23 17  
--32. A method according to claim <sup>17</sup>26 wherein the condition which <sup>is</sup> ~~may be~~ ameliorated by antagonism of 5HT<sub>3</sub> receptors is schizophrenia.--



<sup>24</sup>  
~~33~~. A method according to claim <sup>23</sup>~~32~~ wherein the compound of formula (I) is 2,3,4,5-tetrahydro-5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-1H-pyrido[4,3-b]indol-1-one or a physiologically acceptable salt or solvate thereof.--

<sup>25</sup>  
~~34~~. A method according to claim <sup>23</sup>~~32~~ wherein the compound of formula (I) is 2,3,4,5-tetrahydro-5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-1H-pyrido[4,3-b]indol-1-one hydrochloride.--


<sup>26</sup>  
~~35~~. A compound according to claim 1 which is 5-ethyl-2,3,4,5-tetrahydro-2-[(5-methyl-1H-imidazol-4-yl)methyl]-1H-pyrido[4,3-b]indol-1-one or a physiologically acceptable salt or solvate thereof.--

<sup>27</sup>  
~~36~~. A method according to claim <sup>17</sup>~~26~~ for the treatment of irritable bowel syndrome.--

<sup>28</sup>  
~~37~~. A method according to claim <sup>27</sup>~~36~~ wherein the compound of formula (I) is 2,3,4,5-tetrahydro-5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-1H-pyrido[4,3-b]indol-1-one or a physiologically acceptable salt or solvate thereof.--

<sup>29</sup>  
~~38~~. A method according to claim <sup>27</sup>~~36~~ wherein the compound of formula (I) is 2,3,4,5-tetrahydro-5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-1H-pyrido[4,3-b]indol-1-one hydrochloride.--

--39. A process for the preparation of 2,3,4,5-tetrahydro-5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-1H-pyrido[4,3-b]indol-1-one or a physiologically acceptable salt or solvate thereof, which comprises alkylating a compound of formula (II)



(II)